Table 3.
Incidences and rate ratios for individual tests
| Progressed | Did not progress | Person-years at risk | Annual incidence per 1000 person-years (95% CI) | IRR (95% CI) | |
|---|---|---|---|---|---|
| QuantiFERON-TB Gold In-Tube | |||||
| Test positive | 47/1444 (3·3%) | 1397/1444 (96·7%) | 4649·9 | 10·1 (7·4–13·4) | .. |
| Test negative | 30/4936 (0·6%) | 4906/4936 (99·4%) | 15 921·6 | 1·9 (1·3–2·7) | .. |
| Positive vs negative | .. | .. | .. | .. | 5·4 (3·4–8·5) |
| T-SPOT.TB | |||||
| Test positive | 52/1235 (4·2%) | 1183/1235 (95·8%) | 3926·2 | 13·2 (9·9–17·4) | .. |
| Test negative | 25/5145 (0·5%) | 5120/5145 (99·5%) | 16 645·3 | 1·5 (1·0–2·2) | .. |
| Positive vs negative | .. | .. | .. | .. | 8·8 (5·5–14·2) |
| TST-5 | |||||
| Test positive | 64/2957 (2·2%) | 2893/2957 (97·8%) | 9416·8 | 6·8 (5·2–8·7) | .. |
| Test negative | 13/3423 (0·4%) | 3410/3423 (99·6%) | 11 154·6 | 1·2 (0·6–2·0) | .. |
| Positive vs negative | .. | .. | .. | .. | 5·8 (3·2–10·6) |
| TST-10 | |||||
| Test positive | 58/2151 (2·7%) | 2093/2151 (97·3%) | 6822·3 | 8·5 (6·5–11·0) | .. |
| Test negative | 19/4229 (0·4%) | 4210/4229 (99·6%) | 13 749·2 | 1·4 (0·8–2·2) | .. |
| Positive vs negative | .. | .. | .. | .. | 6·2 (3·7–10·3) |
| TST-15 | |||||
| Test positive | 52/1485 (3·5%) | 1433/1485 (96·5%) | 4674·8 | 11·1 (8·3–14·6) | .. |
| Test negative | 25/4895 (0·5%) | 4870/4895 (99·5%) | 15 896·6 | 1·6 (1·0–2·3) | .. |
| Positive vs negative | .. | .. | .. | .. | 7·1 (4·4–11·4) |
Data are n/N (%), when N is number of participants with that result, and n is number of participants who progressed or did not progress to tuberculosis. IRR=incidence rate ratio. TST=tuberculin skin test. TST-5=TST with threshold ≥5 mm. TST-10=TST with threshold ≥10 mm. TST-15=BCG-dependent definition of TST: ≥15 mm for BCG-vaccinated participant and >5 mm non-vaccinated participant.